Renalytix Plc
RNLX · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -32.7% | 14.6% | 99.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 6.8% | 20.6% | 30.9% | 46.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,293.5% | -1,244.6% | -1,931.7% | -2,187.2% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,461.6% | -1,340.2% | -1,524.4% | -2,329% |
| EPS | -0.62 | -1.1 | -1.24 | -0.98 |
| % Growth | 43.6% | 11.3% | -26.5% | – |
| EPS Diluted | -0.62 | -1.1 | -1.34 | -0.98 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,246% | -1,225.8% | -1,774.2% | -2,381.2% |